GANX
Gain Therapeutics Inc
NASDAQ: GANX · HEALTHCARE · BIOTECHNOLOGY
$1.76
-4.86% today
Updated 2026-04-29
Market cap
$83.70M
P/E ratio
—
P/S ratio
255.50x
EPS (TTM)
$-0.61
Dividend yield
—
52W range
$1 – $4
Volume
0.7M
Gain Therapeutics Inc (GANX) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $-744514.00 | $-1.87M | $-3.24M | $-12.37M | $-14.69M | $-18.87M | $-18.87M | $-18.47M |
| Capital expenditures | $7987.00 | $13723.00 | $20826.00 | $94212.00 | $118953.00 | $15358.00 | $22493.00 | $0.00 |
| Depreciation | — | — | — | — | — | — | — | — |
| Stock-based comp | — | $0.00 | $81640.00 | $839371.00 | $1.53M | $3.26M | $2.39M | $1.80M |
| Free cash flow | $-752501.00 | $-1.88M | $-3.26M | $-12.46M | $-14.81M | $-18.88M | $-18.90M | $-18.47M |
| Investing cash flow | — | — | — | — | — | — | — | — |
| Financing cash flow | — | — | — | — | — | — | — | — |
| Dividends paid | — | — | — | — | — | — | — | — |
| Share repurchases | — | — | — | — | — | — | — | — |
| Debt repayment | — | — | — | — | — | — | — | — |
| Net change in cash | — | — | — | — | $-29.55M | — | — | — |